The Safety of Weight Loss Injections: An Honest Guide

You've read about side effects online and you're not sure what's normal

This is one of the most common concerns our prescribers hear. You've done your research, you've seen reports of nausea, vomiting, fatigue, headaches, and now you're wondering whether the side effects are worth it, or whether something more serious is lurking in the small print. The honest answer is that the gastrointestinal profile is real and well-documented. Nausea is the most frequently reported effect, followed by loose stools, constipation, indigestion and burping. For most people, these effects track closely with dose changes: they tend to arrive a day or two after starting or stepping up, then ease as the body adjusts, usually within one to two weeks.

The reason the dose schedule starts low (2.5mg for tirzepatide, 0.25mg for semaglutide) is specifically to give your digestive system time to settle before the dose increases. Skipping ahead rarely helps. The NHS patient information for tirzepatide lists injection-site reactions, dizziness and headache alongside the GI effects; these are common but not dangerous for the vast majority of users. If you want a fuller picture of how the two options compare on tolerability, the weight loss injections overview covers both side by side.

Fatigue sometimes catches people off guard in the first few weeks. Eating less, adjusting to a new medicine and the body's hormonal shifts all play a part. Staying hydrated and keeping protein intake reasonable makes a genuine difference, something worth raising with your prescriber at review.

When to get medical help, and what cannot wait

Most side effects settle on their own. A few signals should not be waited out. In January 2026 the MHRA issued a Drug Safety Update for GLP-1 receptor agonist medicines, drawing specific attention to acute pancreatitis. It is infrequent, but it can be serious. The key symptom pattern is severe, persistent pain in the abdomen that spreads to the back, sometimes accompanied by vomiting. If that happens, stop treatment and get medical help the same day, do not leave it until morning.

Other situations requiring prompt attention: signs of a severe allergic reaction (swelling of the face, lips or throat, difficulty breathing, a widespread rash); significant dehydration from prolonged vomiting or diarrhoea, which can affect kidney function; gallbladder symptoms such as upper-right abdominal pain after eating; and any sudden changes in vision if you have diabetes. Changes in mood or thoughts of self-harm are rare but listed in the prescribing information and should be discussed with a clinician without delay.

If you are ever uncertain whether a symptom needs attention, contacting your prescriber or calling 111 is always the right call. You can also report a suspected side effect directly at yellowcard.mhra.gov.uk, reports from patients, not just clinicians, feed into the MHRA's ongoing safety monitoring and help build the evidence base for everyone using these medicines.

Who these medicines are not suitable for

Prescription-only status exists precisely because suitability varies. These medicines are not recommended for anyone who is pregnant, breastfeeding or actively trying to conceive, the safety data in those situations is insufficient, and the MHRA advises effective contraception during treatment and for a wash-out period before attempting pregnancy. Neither tirzepatide nor semaglutide is licensed for under-18s.

A personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 rules out GLP-1 medicines entirely. Previous episodes of pancreatitis, certain inflammatory bowel conditions and some kidney impairments require careful prescriber review before proceeding. The full contraindication list lives in the medicine's Summary of Product Characteristics; the eMC (electronic Medicines Compendium) holds both the Mounjaro and Wegovy SmPCs freely accessible.

For tirzepatide specifically, women taking oral contraceptives should add a barrier method for the first four weeks of treatment and for four weeks after every dose increase, because the slowed gastric emptying may reduce pill absorption. NHS England's guidance on weight management injections covers this and the similar consideration around transdermal versus oral HRT. These are practical, manageable adjustments, a prescriber can walk through what applies to you.

How clinical oversight changes the risk picture

Much of the concern around whether weight loss injections are safe relates, rightly, to unsupervised use. Fake pens seized by the MHRA have contained insulin and other undisclosed substances; that is a categorically different risk from a licensed medicine dispensed through a regulated pharmacy. The question of where you buy weight loss injections is not a minor detail, it is central to safety. Any seller offering these medicines without requiring a prescription from a registered prescriber is operating outside the law, and the product itself cannot be assumed to be what it claims.

At nume, every consultation is personally reviewed by a GPhC-registered Independent Prescriber, a real clinician reads your answers, not software. That review checks contraindications, current medicines, relevant history and suitability for the chosen treatment before anything is dispensed, and if you want to understand how the weight loss injection works and what makes it safe, our prescribers are happy to walk through that in detail. Our pharmacy's GPhC registration (number 9012878) can be verified at the GPhC register. You can read more about our clinical team on the prescriber profile page.

If you have questions before starting, our prescribers discuss side effects and suitability as part of every consultation, no question is too small, including questions about which weight loss injection is considered the safest option for your circumstances or how safe the newer weight loss injections on the market are. Check your eligibility and start a free consultation to speak with our clinical team.